Risk Factors for Developing Nonmelanoma Skin Cancer after Lung Transplantation
Table 2
Immunosuppressive regimens at dermatologic examination.
Quasi Intention to Trea
Quasi Per Protoco
All Patients
Everolimus Arm
MMF Arm
Remained on Everolimus
Other immunosuppression
Immunosuppressive Regimen, No.
(n=90)
(n=49)
(n=41)
(n=18)
(n=72)
Tacrolimus, MMF, prednisolone
35 (39)
16 (33)
19 (46)
0 (0)
35 (49)
CsA, MMF, prednisolone
29 (32)
10 (20)
19 (46)
0 (0)
29 (40)
CsA, everolimus, prednisolone
16 (18)
16 (33)
0 (0)
15 (83)
1 (1)
Tacrolimus, azathioprine, prednisolone
3 (3)
2 (4)
1 (2)
0 (0)
3 (4)
Tacrolimus, everolimus, prednisolone
3 (3)
2 (4)
1 (2)
2 (11)
1 (1)
CsA, everolimus, MMF, prednisolone
1 (1)
1 (2)
0 (0)
1 (6)
0 (0)
MMF, sirolimus, prednisolone
1 (1)
1 (2)
0 (0)
0 (0)
1 (1)
Tacrolimus, MMF
1 (1)
0 (0)
1 (2)
0 (0)
1 (1)
Tacrolimus, prednisolone
1 (1)
1 (2)
0 (0)
0 (0)
1 (1)
MMF, mycophenolate mofetil; CsA, cyclosporine A. Patients stratified by original therapy arms from the previous interventional trial “Immunosuppressive therapy with Certican® (Everolimus) after lung transplantation”. Comparing patients from the former everolimus arm, who remained on everolimus until dermatologic exam to all other patients. Percentages have been rounded to whole numbers and may not add up to 100.
